CIBC Bancorp USA’s AbbVie ABBV Stock Holding History

CIBC Bancorp USA’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$468M	Buy	1,860,030 +133,102	+8%	+$28.6M	0.57%	32
2026 Q1	$376M	Buy	+1,726,928	New	+$383M	0.5%	41
2025 Q3	$56.4M	Buy	+243,718	New	+$49.6M	0.31%	53

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CIBC Bancorp USA's ABBV Position: Q2 2026 in Review

CIBC Bancorp USA increased its AbbVie (ABBV) stake by 7.7% in Q2 2026, buying an estimated $28.6M and bringing the position to 1,860,030 shares worth $468M. The position accounts for 0.57% of the portfolio, ranked #32.

CIBC Bancorp USA first reported a position in ABBV in Q3 2025 and has held it in 3 quarters since. 4,063 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

CIBC Bancorp USA held 1,860,030 shares of AbbVie worth $468M as of Q2 2026.
CIBC Bancorp USA bought 133,102 AbbVie shares in Q2 2026, an estimated $28.6M.
AbbVie made up 0.57% of CIBC Bancorp USA's portfolio in Q2 2026, its #32 holding.
CIBC Bancorp USA first reported a position in AbbVie in Q3 2025 and has held it in 3 quarters since.
4,063 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.